Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Abbott Laboratories (ABT): Forecast Dialed Back, But Device Tailwinds Intact—Will Product Innovation Drive the Next Leg of Growth?
Abbott’s Q2F25 results showcased resilient fundamentals and strategic execution, with organic sales ex-COVID up 7.5% and adjusted EPS of $1.26 (+11% Y/Y), despite trimming the full-year revenue growth guide to 6–7% due to lingering COVID testing attrition and China diagnostics softness. Medical Devices remained the enterprise growth engine (+12% organically), led by robust momentum in Diabetes Care (Libre +26% U.S.), Electrophysiology, CRM (AVEIR scaling), and Structural Heart (TriClip, Tendyne). Abbott’s forward-looking innovation pipeline is increasingly central—dual-analyte sensors for glucose and ketones, Volt PFA, and transfemoral mitral valve replacement all position the firm to expand addressable markets and maintain share in high-growth procedural categories. Emerging Market Pharma delivered 8% growth with rising contribution from Key-15 markets and biosimilar filings, reinforcing long-cycle leverage. Gross margin hit 57% (+100bps Y/Y), aided by pricing and easing input costs, while SG&A and R&D spend stayed disciplined, yielding 100bps operating margin expansion. Diagnostics remained a drag (–1.5% Y/Y), but excluding China, Core Lab sales were up 8%, and Alinity upgrades remain on track for 2026. While Medicaid/ACA policy risks cloud the long tail, margin strength, device innovation, and a structurally improving mix support our Hold rating—but can upcoming launches like dual-analyte CGMs and transfemoral mitral valves meaningfully reaccelerate topline in 2026 and re-anchor sentiment?
